. "50686" . . . "Tolerance l\u00E9\u010Dby afatinibem na na\u0161em souboru pacient\u016F"@cs . "Tolerancy of treatment with afatinib on our group of patients"@en . "Tolerance l\u00E9\u010Dby afatinibem na na\u0161em souboru pacient\u016F"@cs . . . "Tolerance l\u00E9\u010Dby afatinibem na na\u0161em souboru pacient\u016F" . "Tolerance l\u00E9\u010Dby afatinibem na na\u0161em souboru pacient\u016F" . "In the group of our 6 patients in the study with afatinib we observed typically adverse events associated with treatment with tyrosine kinase inhibitors. It is a diarrhoea, rash and paronychia. These complications do not affect the comfort of the patients seriously. Other side effects that could be associated with the treatment were transient swelling, epistaxis and conjunctivitis. Treatment with afatinib in our group of patients is very well tolerated."@en . "RIV/00216208:11140/14:10283231!RIV15-MSM-11140___" . "11140" . . . "11" . . "I" . . "Kr\u00E1korov\u00E1, Gabriela" . "3"^^ . "1802-0518" . "3"^^ . "V souboru na\u0161ich 6 pacient\u016F ve studii s afatinibem jsme pozorovali typick\u00E9 ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky v souvislosti s l\u00E9\u010Dbou tyrozin-kin\u00E1zov\u00FDmi inhibitory. Jde o pr\u016Fjmovit\u00E9 stolice, rash a paronychia. D\u00EDky edukaci pacient\u016F tyto komplikace v\u00E1\u017En\u011Bji nenaru\u0161ovali komfort nemocn\u00FDch. Z dal\u0161\u00EDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F, kter\u00E9 mohly m\u00EDt souvislost s l\u00E9\u010Dbou, jsme zaznamenaly p\u0159echodn\u00E9 otoky, epistaxe a konjuktivitidu. L\u00E9\u010Dba pomoc\u00ED afatinibu u na\u0161eho souboru pacient\u016F je p\u0159i dodr\u017Een\u00ED re\u017Eimov\u00FDch preventivn\u00EDch opat\u0159en\u00ED a nasazen\u00ED podp\u016Frn\u00E9 medikace velice dob\u0159e tolerov\u00E1na." . . "RIV/00216208:11140/14:10283231" . "adverse events; EGFR-TKI; NSCLC; afatinib"@en . "Svato\u0148, Martin" . "[E57A26ADA3BD]" . "V souboru na\u0161ich 6 pacient\u016F ve studii s afatinibem jsme pozorovali typick\u00E9 ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky v souvislosti s l\u00E9\u010Dbou tyrozin-kin\u00E1zov\u00FDmi inhibitory. Jde o pr\u016Fjmovit\u00E9 stolice, rash a paronychia. D\u00EDky edukaci pacient\u016F tyto komplikace v\u00E1\u017En\u011Bji nenaru\u0161ovali komfort nemocn\u00FDch. Z dal\u0161\u00EDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F, kter\u00E9 mohly m\u00EDt souvislost s l\u00E9\u010Dbou, jsme zaznamenaly p\u0159echodn\u00E9 otoky, epistaxe a konjuktivitidu. L\u00E9\u010Dba pomoc\u00ED afatinibu u na\u0161eho souboru pacient\u016F je p\u0159i dodr\u017Een\u00ED re\u017Eimov\u00FDch preventivn\u00EDch opat\u0159en\u00ED a nasazen\u00ED podp\u016Frn\u00E9 medikace velice dob\u0159e tolerov\u00E1na."@cs . . . "Pe\u0161ek, Milo\u0161" . . "3"^^ . "Kazuistiky v alergologii, pneumologii a ORL" . . . "3-4" . "Tolerancy of treatment with afatinib on our group of patients"@en . . . "CZ - \u010Cesk\u00E1 republika" .